ABOUT ETON

Eton Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing innovative products utilizing the U.S. Food and Drug Administration’s 505(b)(2) regulatory pathway.

OUR PORTFOLIO

Eton is focused on bringing products to patients through the FDA’s 505(b)(2) regulatory pathway. Its pipeline includes nearly a dozen products in various stages of development across a variety of dosage forms. Eton’s pipeline is focused on innovative 505(b)(2) products and marketed unapproved drugs.

Eton Pharmaceuticals Appoints Paul V. Maier to its Board of Directors

Sep 14, 2017

FULL STORY

Eton Pharma Appoints Dr. Norbert Riedel to its Board of Directors

September 7, 2017

FULL STORY

Eton Pharma Names Sean Brynjelsen Chief Executive Officer and Director

June 23, 2017

FULL STORY

Eton Pharma Announces $20 Million Series A Financing

June 20, 2017

FULL STORY

©2017 by Eton Pharmaceuticals

21925 W. Field Pkwy, Suite 235
Deer Park, IL 60010